The Implications of Obesity as a Disability in Europe
Despite rising obesity in Europe, the EU has yet to approve weight loss drugs from Arena (ARNA), Vivus (VVUS), or Orexigen (OREX).
Orexigen Therapeutics, Inc. (OREX): New Analyst Report from Zacks Equity Research - Zacks Equity Res
Orexigen Therapeutics, Inc. (OREX): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report
Arena Pharmaceuticals Inc. Still Down After CEO's Sale
It says something about the short-term prospects for Arena Pharmaceuticals. And competitors, Orexigen and VIVUS, for that matter.
3 Stocks Even Volatility-Loving Nasdaq Investors Hate
The Nasdaq Composite may be hitting a multidecade high, but pessimists are piling into these three Nasdaq-listed stocks. Are things really as bad as these short-interest figures indicate?
The Next Orphan Drug Multibagger and Future Obesity Champion?
Zafgen's arrival on public markets shakes up the obesity drug war
3 Biotech Stocks with Catalysts Incoming: Spectrum, Orexigen, and Avanir
For companies involved in the development of drugs, a PDUFA decision will meaningfully impact their stocks. With this in mind, there are several PDUFA decisions in upcoming months to watch for.
Are Investors Wrong About Orexigen Therapeutics?
Short-sellers are moving into Orexigen Therapeutics ahead of the company's PDUFA date for its flagship obesity drug. Here's why.